Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates.

Clin Pharmacol Ther · 2019 · PMC8246729 · PMID 30074626

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Our previous meta‐analysis approach showed a decreasing trend of drug clearance as CKD severity increases for CYP2C8 substrate drugs; however, the data were inconclusive due to the overlapping substrate specificity with OATP1B. 13 The present PBPK analysis suggests a negligible change in CYP2C8 function/activity in patients with severe CKD.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.